InCode BioPharmaceutics, Inc.

HOME

Incode BioPharmaceutics, Inc., is developing a product candidate, HC3-1496, that specifically targets the complement pathway. The unique mechanism-of-action of HC3-1496 results in enzymatic depletion of the complement protein C3, the key component for all three pathways of complement activation (alternative, classical, and mannose-lectin). Our preclinical results show rapid depletion of C3 without any observed significant adverse events, including in primates. Importantly, HC3-1496 depletes C3 without the downstream activation of C5, thus preventing the formation of the C5a anaphylatoxin.